SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 26, Issue 33, 2008, Pages 5486-5488

Quality of reporting primary outcomes in phase II cancer trials

(3) Riechelmann, Rachel P a Dounaevskaia, Vera b,c Krzyzanowska, Monika K b,c

a FEDERAL UNIVERSITY OF SÃO PAULO (Brazil)

b UNIVERSITY OF TORONTO (Canada)

c PRINCESS MARGARET HOSPITAL (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; LETTER; METHODOLOGY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; NEOPLASMS; PUBLISHING;

EID: 56749133305 PISSN: 0732183X EISSN: None Source Type: Journal
DOI: 10.1200/JCO.2008.19.7343 Document Type: Letter

Times cited : (5)

References (9)

1
- 0038473996
- Trends in clinical trials reports in common cancers between 1989 and 2000
- Hillner BE: Trends in clinical trials reports in common cancers between 1989 and 2000. J Clin Oncol 21:1850-1858, 2003
- (2003) J Clin Oncol , vol.21 , pp. 1850-1858
- Hillner, B.E.¹

2
- 0031797332
- Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism
- Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. Ann Oncol 9:1047-1052, 1998
- (1998) Ann Oncol , vol.9 , pp. 1047-1052
- Eisenhauer, E.A.¹

3
- 0033984551
- Content and quality of currently published phase II cancer trials
- Mariani L, Marubini E: Content and quality of currently published phase II cancer trials. J Clin Oncol 18:429-436, 2000
- (2000) J Clin Oncol , vol.18 , pp. 429-436
- Mariani, L.¹ Marubini, E.²

4
- 1942520219
- Five-year change in statistical designs of phase II trials published in leading cancer journals
- Thezenas S, Duffour J, Culine S, et al: Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer 40:1244-1249, 2004
- (2004) Eur J Cancer , vol.40 , pp. 1244-1249
- Thezenas, S.¹ Duffour, J.² Culine, S.³

5
- 38649107161
- Source of funding, conflict of interest (COI), and the interpretation of cancer clinical trials
- suppl; abstr 6530, 329s
- Riechelmann RP, Dounaevskaia V, Taback N, et al: Source of funding, conflict of interest (COI), and the interpretation of cancer clinical trials. J Clin Oncol 25:329s, 2007 (suppl; abstr 6530)
- (2007) J Clin Oncol , vol.25
- Riechelmann, R.P.¹ Dounaevskaia, V.² Taback, N.³

6
- 0020108590
- One-sample multiple testing procedure for phase II clinical trials
- Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
- (1982) Biometrics , vol.38 , pp. 143-151
- Fleming, T.R.¹

7
- 84871470611
- Trends in the quality of abstracts of articles describing randomized controlled cancer trials (RCTs) from 1975-2004
- suppl; abstr 6541, 332s
- Cescon DW, Booth CM, Wang L, et al: Trends in the quality of abstracts of articles describing randomized controlled cancer trials (RCTs) from 1975-2004. J Clin Oncol 25:332s, 2007 (suppl; abstr 6541)
- (2007) J Clin Oncol , vol.25
- Cescon, D.W.¹ Booth, C.M.² Wang, L.³

8
- 0022361467
- The phase II trial
- Wittes RE, Marsoni S, Simon R, et al: The phase II trial. Cancer Treat Rep 69:1235-1239, 1985
- (1985) Cancer Treat Rep , vol.69 , pp. 1235-1239
- Wittes, R.E.¹ Marsoni, S.² Simon, R.³

9
- 0038730811
- Statistical design in phase II clinical trials and its application in breast cancer
- Perrone F, Di Maio M, De Maio E, et al: Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncol 4:305-311, 2003
- (2003) Lancet Oncol , vol.4 , pp. 305-311
- Perrone, F.¹ Di Maio, M.² De Maio, E.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.